← Back to headlines
Deutsche Bank Upgrades Merck to Buy, Sees Clear Path Beyond Keytruda Patent Cliff
Deutsche Bank has upgraded Merck (MRK) to a 'Buy' rating, expressing optimism about the company's future beyond the patent expiration of its key drug, Keytruda.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
